Edwards Lifesciences

EW · NYSE

$88.29+$1.07 (+1.23%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $87.22

EW analyst rating

BuyConsensus of 21 analysts over the last 12 months. 76% rate it a buy.

Strong buy0
Buy16
Hold5
Underperform0
Sell0

12-month price target · 32 analysts

Average $101.84 (+15.3% upside)

Low: $85.85
Now: $88.29
High: $115.50

Upgrades and downgrades

The latest rating actions, newest first

EW analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Oct 7, 2026	Initiates	Overweight	$110.00	68%
BTIG	Sep 11, 2026	Maintains	Buy	$110.00	56%
UBS	Jul 28, 2026	Initiates	Neutral → Buy	$110.00	43%
Leerink Partners	Jul 24, 2026	Upgrade	Market Perform → Outperform	$87.00 → $101.00	41%
JP Morgan	Jul 24, 2026	Maintains	Overweight	$100.00 → $105.00	56%
Piper Sandler	Jul 24, 2026	Maintains	Overweight	$100.00 → $101.00	51%
Truist Securities	Jul 16, 2026	Maintains	Hold	$90.00 → $95.00	50%
Mizuho	Jul 15, 2026	Maintains	Outperform	$100.00 → $105.00	56%
RBC Capital	Jul 13, 2026	Maintains	Outperform	$100.00 → $110.00	49%
Citigroup	Jul 8, 2026	Maintains	Buy	$101.00 → $110.00	60%

The case for and against

Updated Oct 14, 2026

Bull case

Edwards Lifesciences is well positioned fundamentally because its TAVR business appears stabilized and could re-accelerate as CMS broadens coverage to asymptomatic severe aortic stenosis, potentially removing barriers and lifting procedure volumes. Its second quarter reinforced that view, with total revenue of $1.741 billion, TAVR revenue of $1.26 billion, TMTT revenue up 45.5% ex-FX to $195.9 million, and adjusted operating margin improving to 30.0%, showing both growth and operating leverage. Beyond TAVR, a durable competitive moat, 15+ years of clinical data, new mitral and tricuspid launches, and guided annual margin expansion support a long-term growth profile near 10% while tariff headwinds are already reflected in guidance.

Bear case

Edwards Lifesciences is facing a challenging risk-reward setup despite its leadership in surgical tissue heart valves and transcatheter valve technologies, because its valuation already reflects a rich 30.5x multiple that sits at the high end of the large-cap medical device peer group. The company’s roughly 60% international revenue exposure adds currency and execution risk, while commercial hiccups, regulatory and NCD delays, product recalls, and negative clinical data readouts could disrupt the expected growth from its mitral, tricuspid, and heart failure pipeline. Although the business has a solid growth profile and margin expansion potential, these catalysts may be insufficient to offset elevated expectations and competition, leaving the stock vulnerable if execution slips.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.